At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 58 enrolled
Drug / intervention
neostigmine/glycopyrrolate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Time to Full Recovery From Muscle Paralysis (TOF>0.9) and Extubation Using Sugammadex Versus Neostigmine/Glycopyrrolate in Patients With Pulmonary Disease in the Outpatient Bronchoscopy Suite
In Brief
A Phase 4 clinical trial evaluating neostigmine/glycopyrrolate and sugammadex for Neuromuscular Blockade and Chronic Obstructive Pulmonary Disease. Completed, enrolled 58 participants across 1 site.
Detailed Summary
A prospective blinded randomized clinical trial to compare time to extubation using Sugammadex versus Neostigmine/glycopyrrolate as reversal agents after use of neuromuscular blockade agents in an outpatient bronchoscopy suite.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartApr 2021
Primary CompletionJul 2023
TodayJul 2026
First PostedOct 28, 2020
Enrollment StartApr 8, 2021
Primary CompletionJul 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.7 years ago
Interventions
neostigmine/glycopyrrolatedrug
neuromuscular blockade reversal agents
sugammadexdrug
neuromuscular blockade reversal agent